Galderma’s CFO Thomas Dittrich To Depart

Thomas Dittrich will be stepping down from his role as Chief Financial Officer at Galderma. Mr. Dittrich will remain with the company as Chief Financial Officer through Q2 2026 to ensure a seamless transition through the close of the 2025 fiscal year. A successor will be announced in due course, the Company states.

Laura Sandler Named New COO at Oruka Therapeutics, Inc

Laura Sandler is the new Chief Operating Officer at Oruka Therapeutics, Inc. Ms. Sandler, who joined Oruka in 2024 as SVP of Operations, played a pivotal role in progressing Oruka’s programs from preclinical stages into clinical trials with speed and precision.

Before Oruka, Ms. Sandler served as SVP of Development Operations at CRISPR Therapeutics, where she was instrumental in accelerating exa-cel—the first CRISPR-based medicine to receive regulatory approval—through clinical development. She began her career in clinical operations and has held increasingly senior roles at MedImmune, Quintiles, Novartis, and bluebird bio.

Incyte Taps Bill Meury as New CEO

Bill Meury is Incyte’s new CEO. He is replacing Hervé Hoppenot, who led the Company for the past 11 years. Meury, whose appointment is effective immediately, previously ran Anthos Therapeutics, which he sold this year to Novartis, and Karuna Therapeutics, which Bristol Myers Squibb bought for $14 billion in 2023. Meury also served as Chief Commercial Officer at Allergan. Mr. Hoppenot will remain on Incyte’s board of directors through the end of this year to aid Meury’s transition into the CEO role.